Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
BIG PHARMA AND ECONOMICS
By Health Care Renewal
***
Aducanumab, sold under the brand name Aduhelm, is a medication designed to treat Alzheimer’s disease. It is an amyloid beta-directed monoclonal antibody that targets aggregated forms of amyloid beta found in the brains of people with Alzheimer’s disease to reduce its buildup.
LINK: https://hcrenewal.blogspot.com/2021/07/money-and-aducanumab.html
***
RELATED: https://hcrenewal.blogspot.com/2021/07/the-future-of-aducanumab-as-medicine.html
CITE: https://www.r2library.com/Resource/Title/0826102549
YOUR COMMENTS ARE APPRECIATED.
***
Thank You
***
Share this:
Filed under: Breaking News, Drugs and Pharma, Health Economics, Healthcare Finance | Tagged: Aducanumab, Alzheimer’s disease, Health Care Renewal |
The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants 
Specialty Drugs Accounted For 51.4% of The Net Cost in Medicaid
A recent report by Magellan Health “The Magellan Rx Management Medicaid Pharmacy Trend Report” includes data from Magellan Rx’s Medicaid FFS pharmacy programs in 25 states and the District of Columbia. The material is reviewed and supported by a team of Magellan Rx experts with broad national expertise, including 369 years of combined pharmacy benefit administration (PBA) experience. The report found:
• In 2020, specialty drugs accounted for 51.4% of the net cost in Medicaid, a trend predicted for the last five years. A constant imbalance in spend, specialty drugs only accounted for 1.3% of utilization.
• 2020 traditional net cost trend for Medicaid FFS was positive for the first time in five years with the introduction of new-to-market drugs.
• Medicaid FFS top drug classes remained almost identical to previous years – with HIV/AIDS and antipsychotics accounting for more than 19.8% of the total net drug spend.
• With a steady increase in pipeline drugs, most key conditions will experience increased trend over the next three years. Comparatively, conditions with generic drug introductions or specialized management strategies will see a decrease.
Source: Magellan Health via BusinessWire, November 15, 2021
LikeLike
Biogen’s new Alzheimer’s drug, Aduhelm
https://www.msn.com/en-us/health/medical/this-one-drug-threatens-to-tank-medicares-entire-prescription-drug-model/ar-AARshJd?li=BBnb7Kz
DEM
LikeLike
Price Update
https://www.msn.com/en-us/health/medical/biogen-to-slash-price-of-its-alzheimer-drug-in-half/ar-AARZVan?li=BBnb7Kz
DEM
LikeLike